Targeting hepatic glucose metabolism in the treatment of type 2 diabetes

Citation:

A. K. Rines, Sharabi, K. , Tavares, C. D. , and Puigserver, P. . 2016. “Targeting Hepatic Glucose Metabolism In The Treatment Of Type 2 Diabetes”. Nat Rev Drug Discov, 15, Pp. 786-804.

Abstract:

Type 2 diabetes mellitus is characterized by the dysregulation of glucose homeostasis, resulting in hyperglycaemia. Although current diabetes treatments have exhibited some success in lowering blood glucose levels, their effect is not always sustained and their use may be associated with undesirable side effects, such as hypoglycaemia. Novel antidiabetic drugs, which may be used in combination with existing therapies, are therefore needed. The potential of specifically targeting the liver to normalize blood glucose levels has not been fully exploited. Here, we review the molecular mechanisms controlling hepatic gluconeogenesis and glycogen storage, and assess the prospect of therapeutically targeting associated pathways to treat type 2 diabetes.

Notes:

Rines, Amy KSharabi, KfirTavares, Clint D JPuigserver, PereengF32 DK102293/DK/NIDDK NIH HHS/R24 DK080261/DK/NIDDK NIH HHS/R01 DK081418/DK/NIDDK NIH HHS/R01 DK089883/DK/NIDDK NIH HHS/R01 DK069966/DK/NIDDK NIH HHS/ReviewEnglandNat Rev Drug Discov. 2016 Nov;15(11):786-804. doi: 10.1038/nrd.2016.151. Epub 2016 Aug 12.